A press release today highlighting a new drug, based on Arazine, that is claimed to help both the redness and papules and pustules of rosacea through its ability to down regulate G-protein coupled receptor (GPCR) signaling.
The company developing DMT 210, Dermata, is releasing results from their phase 1 trials, and are looking to commence phase 2 trials in late 2016.
Rosacea sufferers will be more familiar with the previous name of DMT 210 – namely SIG990, which was licensed to Dermata from Signum in 2015.
So what we are seeing with DMT 210 is a continuation of the slow process whereby a promising active molecule makes it way towards becoming a proven rosacea treatment.
SAN DIEGO, Sept. 28, 2016 /PRNewswire/ — Dermata Therapeutics, LLC, a biotechnology company focused on developing innovative medical dermatology products for dermatologists and their patients, today announces positive findings from their 28-day Phase 1 Pharmacokinetic Study in Acne Rosacea patients with their lead compound, DMT210.
The results from the Phase 1 study show that DMT210 has minimal systemic exposure, an acceptable safety profile and appears well tolerated by patients, with most reported local skin reactions as mild.
Dermata also collected efficacy data, producing meaningful results, by measuring the four main clinical endpoints for rosacea:
- reduction in lesion counts,
- investigator global assessment in rosacea,
- clinician’s assessment of erythema, and
- patient’s severity assessment of erythema.
These results are consistent with the findings of their non-clinical data, which indicated DMT210 may be effective to treat both the erythema and inflammation (papules and pustules) associated with rosacea.
We can see that the products DMT210 and DMT220 are the same active ingredient as SMT200 but targeted to facial and ocular rosacea instead.
Dermata: Products in Development
DMT200 is an Isoprenylcysteine (IPC) analog that modulates toll-like receptors and G-protein signaling. It is a new chemical entity developed as a more potent version of the IPC analog Arazine, a cosmeceutical that was licensed to Elizabeth Arden for treatment of patients with facial redness.
DMT200 is specifically designed as a structural mimic of the amino acid tail found at the C-terminus of G-proteins with the purpose to downregulate the inflammatory response through G-protein coupled receptor (GPCR) signaling. Because of DMT200’s effect on multiple inflammatory pathways, we are currently evaluating a topical formulation for multiple dermatologic diseases. In addition, we have begun development work on a novel ophthalmic formulation.
DMT210 is our topical gel formulation of DMT200. Due to the wide distribution of GPCRs in the skin we plan to develop DMT210 for the treatment of rosacea, atopic dermatitis and acne vulgaris.
Rosacea: DMT210 has demonstrated downregulation of toll-like receptor 2 (TLR2), lowering IL-8 production, which ultimately would reduce erythema associated with rosacea.
Moreover, DMT210 also exhibits a reduction in IL-6, which is a powerful inflammatory mediator. T
hus, DMT210 has the potential to be the first topical treatment to reduce both the erythema and the inflammation (papules and pustules) of rosacea.
DMT220, which is currently being formulated, will be our novel ophthalmic formulation. We plan to develop DMT220 for the treatment of ocular rosacea, because it can be treated by dermatologists.
Ocular Rosacea: The ocular surface is also populated with GPCRs, suggesting that a topical ophthalmic formulation using DMT200 could be effective at targeting similar pathways as in the skin.
Therefore, since the same inflammatory processes that occur in dermal rosacea are also expressed in ocular rosacea, there is good scientific rationale to develop DMT220 for ocular rosacea.
- DRx AFC Medirepair (Arazine) now available in Japan
- SIG990 Gains IND Status for Rosacea Redness and Lesions
- SIG990 Excellent for Redness, several years away
- 9 New Drugs in Development for Rosacea
- New & Emerging Rosacea Treatments Update
- What’s Hot in New Rosacea Treatments?
- Trial Watch: New Treatments Coming Soon
- Why Do New Drugs take SO LONG to be Developed?